Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 G1 TherapeuticsDynavax TechnologiesHumanigenVectura GroupSyndax Pharmaceuticals
SymbolNASDAQ:GTHXNASDAQ:DVAXNASDAQ:HGENOTCMKTS:VEGPFNASDAQ:SNDX
Price Information
Current Price$25.57$10.07$17.25$1.43$22.16
52 Week RangeBuyBuyBuyHoldBuy
MarketRank™
Overall Score1.51.71.60.51.6
Analysis Score3.53.53.40.03.4
Community Score2.42.53.32.32.5
Dividend Score0.00.00.00.00.0
Ownership Score1.71.70.80.01.7
Earnings & Valuation Score0.00.60.60.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyHoldBuy
Consensus Price Target$49.17$16.33$29.50N/A$28.55
% Upside from Price Target92.28% upside62.20% upside71.01% upsideN/A28.82% upside
Trade Information
Market Cap$1.07 billion$1.14 billion$922.56 million$864.09 million$1.07 billion
Beta2.441.34-0.790.691.8
Average Volume1,576,9935,701,4152,591,4711,717672,291
Sales & Book Value
Annual RevenueN/A$35.22 millionN/A$227.68 million$1.52 million
Price / SalesN/A32.38N/A3.80703.23
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$6.80 per share$0.10 per share($0.63) per share$0.89 per share$1.16 per share
Price / BookN/A100.70N/A1.6119.10
Profitability
Net Income$-122,450,000.00$-152,600,000.00$-10,290,000.00$-28,220,000.00$-56,050,000.00
EPS($3.27)($1.87)N/A($0.04)($1.84)
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E RatioN/AN/A4.2123.83N/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-256.92%N/AN/A-4,656.63%
Return on Equity (ROE)-49.35%-193.85%-302.90%N/A-77.47%
Return on Assets (ROA)-41.53%-23.45%-174.74%N/A-52.27%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.10%2.59%N/A0.02%0.15%
Current Ratio7.45%4.35%6.19%2.52%11.71%
Quick Ratio7.45%3.47%6.19%1.98%11.71%
Ownership Information
Institutional Ownership Percentage77.89%80.02%30.18%N/A83.78%
Insider Ownership Percentage14.49%13.33%37.50%N/A9.50%
Miscellaneous
Employees1222451048043
Shares Outstanding41.96 million113.26 million53.48 million604.26 million48.24 million
Next Earnings Date5/5/2021 (Estimated)5/6/2021 (Estimated)5/21/2021 (Estimated)N/A5/6/2021 (Estimated)
OptionableOptionableOptionableOptionableNot OptionableOptionable
SourceHeadline
Syndax Pharma’s Axatilimab Receives Orphan Drug Designation For Treatment Of Chronic Lung DiseaseSyndax Pharma’s Axatilimab Receives Orphan Drug Designation For Treatment Of Chronic Lung Disease
finance.yahoo.com - April 9 at 12:19 PM
Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Idiopathic Pulmonary FibrosisSyndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Idiopathic Pulmonary Fibrosis
finance.yahoo.com - April 8 at 9:13 PM
Is SNDX Stock A Buy or Sell?Is SNDX Stock A Buy or Sell?
finance.yahoo.com - April 8 at 4:13 PM
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 6.7%Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 6.7%
americanbankingnews.com - April 1 at 12:36 PM
Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Chronic Graft Versus Host DiseaseSyndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Chronic Graft Versus Host Disease
finance.yahoo.com - March 31 at 7:23 AM
Is Syndax Pharmaceuticals (NASDAQ:SNDX) Using Debt In A Risky Way?Is Syndax Pharmaceuticals (NASDAQ:SNDX) Using Debt In A Risky Way?
finance.yahoo.com - March 15 at 5:07 PM
Syndax Pharmaceuticals (NASDAQ:SNDX) Downgraded by Zacks Investment Research to "Sell"Syndax Pharmaceuticals (NASDAQ:SNDX) Downgraded by Zacks Investment Research to "Sell"
marketbeat.com - March 12 at 8:19 AM
Syndax Pharmaceuticals, Inc. (SNDX) CEO Dr. Briggs Morrison on Q4 2020 Results - Earnings Call TranscriptSyndax Pharmaceuticals, Inc. (SNDX) CEO Dr. Briggs Morrison on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - March 10 at 6:15 PM
Syndax Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call PresentationSyndax Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation
seekingalpha.com - March 9 at 5:29 PM
Syndax Posts Better-Than-Feared Quarterly Loss, Sales Beat EstimatesSyndax Posts Better-Than-Feared Quarterly Loss, Sales Beat Estimates
finance.yahoo.com - March 9 at 7:03 AM
Syndax: Q4 Earnings SnapshotSyndax: Q4 Earnings Snapshot
finance.yahoo.com - March 8 at 8:52 PM
Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business UpdateSyndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update
finance.yahoo.com - March 8 at 8:52 PM
Syndax Pharmaceuticals: Q4 Earnings InsightsSyndax Pharmaceuticals: Q4 Earnings Insights
finance.yahoo.com - March 8 at 8:52 PM
Syndax to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 8, 2021Syndax to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 8, 2021
finance.yahoo.com - March 1 at 8:01 AM
Syndax Pharmaceuticals To Be Added to the NASDAQ Biotechnology IndexSyndax Pharmaceuticals To Be Added to the NASDAQ Biotechnology Index
finance.yahoo.com - December 18 at 7:34 AM
Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional SharesSyndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - December 11 at 8:39 PM
Implied Volatility Surging for Syndax Pharmaceuticals (SNDX) Stock OptionsImplied Volatility Surging for Syndax Pharmaceuticals (SNDX) Stock Options
nasdaq.com - December 7 at 5:09 PM
News for Syndax Pharmaceuticals IncNews for Syndax Pharmaceuticals Inc
markets.businessinsider.com - November 30 at 5:08 PM
Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD ExpertsSyndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts
finance.yahoo.com - November 30 at 8:31 AM
Syndax Announces Presentation at Stifel 2020 Virtual Healthcare ConferenceSyndax Announces Presentation at Stifel 2020 Virtual Healthcare Conference
finance.yahoo.com - November 11 at 7:53 AM
Syndax Pharmaceuticals to Present Updated Data from Phase 1 Trial of Axatilimab in cGVHD During Oral Session at the 62nd ASH Annual MeetingSyndax Pharmaceuticals to Present Updated Data from Phase 1 Trial of Axatilimab in cGVHD During Oral Session at the 62nd ASH Annual Meeting
finance.yahoo.com - November 4 at 5:40 PM
Heres what Wall Street expects from Syndax Pharmaceuticalss earnings reportHere's what Wall Street expects from Syndax Pharmaceuticals's earnings report
markets.businessinsider.com - November 3 at 3:09 PM
Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2020 Results - Earnings Call TranscriptSyndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 3 at 9:54 AM
Syndax Pharmaceuticals EPS misses by $0.02, misses on revenueSyndax Pharmaceuticals EPS misses by $0.02, misses on revenue
seekingalpha.com - November 2 at 6:26 PM
Syndax: 3Q Earnings SnapshotSyndax: 3Q Earnings Snapshot
sfchronicle.com - November 2 at 6:26 PM
Syndax Pharmaceuticals, Inc. to Host Earnings CallSyndax Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 2 at 6:26 PM
DateCompanyBrokerageAction
4/9/2021G1 TherapeuticsNeedham & Company LLCReiterated Rating
11/17/2020G1 TherapeuticsRaymond JamesDowngrade
10/5/2020G1 TherapeuticsHC WainwrightReiterated Rating
8/20/2020G1 TherapeuticsWedbushReiterated Rating
8/9/2020G1 TherapeuticsCowenReiterated Rating
6/26/2020G1 TherapeuticsRoth CapitalInitiated Coverage
5/12/2020G1 TherapeuticsJPMorgan Chase & Co.Lower Price Target
1/7/2020G1 TherapeuticsBTIG ResearchBoost Price Target
12/18/2020Dynavax TechnologiesWilliam BlairReiterated Rating
6/15/2020Dynavax TechnologiesEvercore ISIInitiated Coverage
7/10/2019Dynavax TechnologiesCantor FitzgeraldUpgrade
5/24/2019Dynavax TechnologiesRoyal Bank of CanadaLower Price Target
12/23/2020HumanigenNational SecuritiesInitiated Coverage
12/22/2020HumanigenJefferies Financial GroupInitiated Coverage
1/25/2021Vectura GroupPeel HuntDowngrade
1/22/2021Vectura GroupCitigroupDowngrade
2/18/2021Syndax PharmaceuticalsB. RileyInitiated Coverage
12/8/2020Syndax PharmaceuticalsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
12/8/2020Syndax PharmaceuticalsSmith Barney CitigroupBoost Price Target
12/7/2020Syndax PharmaceuticalsMorgan StanleyBoost Price Target
12/7/2020Syndax PharmaceuticalsBarclaysBoost Price Target
12/2/2020Syndax PharmaceuticalsStifel NicolausInitiated Coverage
5/25/2020Syndax PharmaceuticalsNomuraReiterated Rating
4/28/2020Syndax PharmaceuticalsRobert W. BairdBoost Price Target
3/26/2020Syndax PharmaceuticalsNomura SecuritiesReiterated Rating
(Data available from 4/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.